Podsadecki T - Search Results

1

Epigenetic analysis of the IFNλ3 gene identifies a novel marker for response to therapy in HCV-infected subjects.

Waring JF, Davis JW, Dumas E, Cohen D, Idler K, Abel S, Georgantas R, Podsadecki T, Dutta S. Waring JF, et al. Among authors: podsadecki t. J Viral Hepat. 2017 May;24(5):397-403. doi: 10.1111/jvh.12661. Epub 2016 Dec 20. J Viral Hepat. 2017. PMID: 27925355

2

Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.

Waring JF, Dumas EO, Abel S, Coakley E, Cohen DE, Davis JW, Podsadecki T, Dutta S. Waring JF, et al. Among authors: podsadecki t. J Viral Hepat. 2016 Feb;23(2):96-104. doi: 10.1111/jvh.12470. Epub 2015 Oct 5. J Viral Hepat. 2016. PMID: 26436610 Clinical Trial.

3

Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.

Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, Bernstein B, Awni W, Menon R. Badri P, et al. Among authors: podsadecki t. Am J Transplant. 2015 May;15(5):1313-22. doi: 10.1111/ajt.13111. Epub 2015 Feb 23. Am J Transplant. 2015. PMID: 25708713 Free PMC article. Clinical Trial.

4

Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.

Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Poordad F, et al. Among authors: podsadecki t. Clin Infect Dis. 2015 Feb 15;60(4):608-10. doi: 10.1093/cid/ciu865. Epub 2014 Nov 2. Clin Infect Dis. 2015. PMID: 25365973

5

Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.

Khatri A, Mensing S, Podsadecki T, Awni W, Menon R, Dutta S. Khatri A, et al. Among authors: podsadecki t. Clin Drug Investig. 2016 Aug;36(8):625-35. doi: 10.1007/s40261-016-0407-x. Clin Drug Investig. 2016. PMID: 27153823 Clinical Trial.

6

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.

King JR, Dutta S, Cohen D, Podsadecki TJ, Ding B, Awni WM, Menon RM. King JR, et al. Antimicrob Agents Chemother. 2015 Nov 23;60(2):855-61. doi: 10.1128/AAC.01913-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26596948 Free PMC article. Clinical Trial.

7

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.

Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Menon RM, et al. Among authors: podsadecki tj. Br J Clin Pharmacol. 2016 May;81(5):929-40. doi: 10.1111/bcp.12873. Epub 2016 Feb 24. Br J Clin Pharmacol. 2016. PMID: 26710243 Free PMC article. Clinical Trial.

8

Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.

Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, Menon R. Khatri A, et al. Among authors: podsadecki t. Clin Infect Dis. 2016 Apr 15;62(8):972-9. doi: 10.1093/cid/civ1213. Epub 2016 Jan 5. Clin Infect Dis. 2016. PMID: 26740513 Clinical Trial.

9

Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.

Lin CW, Menon R, Liu W, Podsadecki T, Shulman N, DaSilva-Tillmann B, Awni W, Dutta S. Lin CW, et al. Among authors: podsadecki t. Clin Drug Investig. 2017 Jul;37(7):647-657. doi: 10.1007/s40261-017-0520-5. Clin Drug Investig. 2017. PMID: 28378135

10

Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.

Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM. Polepally AR, et al. Clin Pharmacokinet. 2016 Aug;55(8):1003-14. doi: 10.1007/s40262-016-0373-8. Clin Pharmacokinet. 2016. PMID: 26895022 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page